Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.

Girard E, Eon-Marchais S, Olaso R, Renault AL, Damiola F, Dondon MG, Barjhoux L, Goidin D, Meyer V, Le Gal D, Beauvallet J, Mebirouk N, Lonjou C, Coignard J, Marcou M, Cavaciuti E, Baulard C, Bihoreau MT, Cohen-Haguenauer O, Leroux D, Penet C, Fert-Ferrer S, Colas C, Frebourg T, Eisinger F, Adenis C, Fajac A, Gladieff L, Tinat J, Floquet A, Chiesa J, Giraud S, Mortemousque I, Soubrier F, Audebert-Bellanger S, Limacher JM, Lasset C, Lejeune-Dumoulin S, Dreyfus H, Bignon YJ, Longy M, Pujol P, Venat-Bouvet L, Bonadona V, Berthet P, Luporsi E, Maugard CM, Noguès C, Delnatte C, Fricker JP, Gesta P, Faivre L, Lortholary A, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Servant N, Boland A, Mazoyer S, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.

Int J Cancer. 2019 Apr 15;144(8):1962-1974. doi: 10.1002/ijc.31921. Epub 2018 Nov 13.

2.

[Do controlled ovarian hyperstimulations and cryopreservations promote recurrences after breast cancer?]

Bergamini ML, Maugard CM, Mathelin C.

Gynecol Obstet Fertil Senol. 2017 Mar;45(3):172-179. doi: 10.1016/j.gofs.2017.01.008. Epub 2017 Mar 1. Review. French.

PMID:
28259703
3.

First case report of an adrenocortical carcinoma caused by a BRCA2 mutation.

El Ghorayeb N, Grunenwald S, Nolet S, Primeau V, Côté S, Maugard CM, Lacroix A, Gaboury L, Bourdeau I.

Medicine (Baltimore). 2016 Sep;95(36):e4756. doi: 10.1097/MD.0000000000004756.

4.

[Multidisciplinary team meetings settings on the management of women at high risk of inherited breast cancer. A French study].

Gillmann F, Cordier C, Taris N, Mathelin C, Maugard CM.

Bull Cancer. 2016 Jun;103(6):571-83. doi: 10.1016/j.bulcan.2016.03.006. Epub 2016 May 11. French.

PMID:
27178881
5.

GENESIS: a French national resource to study the missing heritability of breast cancer.

Sinilnikova OM, Dondon MG, Eon-Marchais S, Damiola F, Barjhoux L, Marcou M, Verny-Pierre C, Sornin V, Toulemonde L, Beauvallet J, Le Gal D, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Dugast C, Gesta P, Fricker JP, Noguès C, Faivre L, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis C, Venat-Bouvet L, Demange L, Dreyfus H, Frenay M, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Chevrier A, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Colas C, Fert-Ferrer S, Penet C, Frebourg T, Collonge-Rame MA, Barouk-Simonet E, Layet V, Leroux D, Cohen-Haguenauer O, Prieur F, Mouret-Fourme E, Cornélis F, Jonveaux P, Bera O, Cavaciuti E, Tardivon A, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, Andrieu N.

BMC Cancer. 2016 Jan 12;16:13. doi: 10.1186/s12885-015-2028-9.

6.

Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers.

Lecarpentier J, Noguès C, Mouret-Fourme E, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Bonadona V, Fricker JP, Berthet P, Caron O, Coupier I, Pujol P, Faivre L, Gesta P, Eisinger F, Mari V, Gladieff L, Lortholary A, Luporsi E, Leroux D, Venat-Bouvet L, Maugard CM, Colas C, Tinat J, Lasset C, Andrieu N; GENEPSO.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):698-707. doi: 10.1158/1055-9965.EPI-14-0884. Epub 2015 Jan 22.

7.

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Prim N, Legrain M, Guerin E, Mennecier B, Weingertner N, Voegeli AC, Guenot D, Maugard CM, Quoix AE, Beau-Faller M.

Eur Respir Rev. 2014 Sep;23(133):390-2. doi: 10.1183/09059180.00009313. No abstract available.

8.

Germline BAP1 mutations predispose to renal cell carcinomas.

Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d'Enghien C, Richaudeau B, Renaudin X, Sellers J, Nicolas A, Sastre-Garau X, Desjardins L, Gyapay G, Raynal V, Sinilnikova OM, Andrieu N, Manié E, de Pauw A, Gesta P, Bonadona V, Maugard CM, Penet C, Avril MF, Barillot E, Cabaret O, Delattre O, Richard S, Caron O, Benfodda M, Hu HH, Soufir N, Bressac-de Paillerets B, Stoppa-Lyonnet D, Stern MH.

Am J Hum Genet. 2013 Jun 6;92(6):974-80. doi: 10.1016/j.ajhg.2013.04.012. Epub 2013 May 16.

9.

A focus group study on breast cancer risk presentation: one format does not fit all.

Dorval M, Bouchard K, Chiquette J, Glendon G, Maugard CM, Dubuisson W, Panchal S, Simard J.

Eur J Hum Genet. 2013 Jul;21(7):719-24. doi: 10.1038/ejhg.2012.248. Epub 2012 Nov 21.

10.

Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.

Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM.

Cancer Prev Res (Phila). 2012 May;5(5):765-77. doi: 10.1158/1940-6207.CAPR-11-0547. Epub 2012 Mar 8.

11.

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.

Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D, Tonin PN.

Fam Cancer. 2010 Dec;9(4):507-17. doi: 10.1007/s10689-010-9372-3.

PMID:
20694749
12.

Higher frequency of familial clustering of prostate cancer in French-Canadian men.

Filion E, Taussky D, Bahary JP, Maugard CM.

J Urol. 2007 Oct;178(4 Pt 1):1265-9; discussion 1270. Epub 2007 Aug 14.

PMID:
17698103
13.

A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.

Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM.

Fam Cancer. 2007;6(4):491-7. Epub 2007 Jul 17.

PMID:
17636423
14.

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.

Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN.

Breast Cancer Res Treat. 2008 Apr;108(3):399-408. Epub 2007 May 31.

PMID:
17541742
15.

Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).

Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM.

Mol Carcinog. 2007 Oct;46(10):872-85.

PMID:
17455221
16.

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.

Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN.

Clin Genet. 2006 Oct;70(4):320-9.

PMID:
16965326
17.

The contribution of germline rearrangements to the spectrum of BRCA2 mutations.

Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillet P, Philippe C, Lortholary A, Gesta P, Bézieau S, Toulas C, Gladieff L, Maugard CM, Provencher DM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frébourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M.

J Med Genet. 2006 Sep;43(9):e49.

18.

Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling.

Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM.

Oncogene. 2005 Jul 7;24(29):4672-87.

PMID:
15940270
19.

Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.

Samouëlian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM.

Cancer Chemother Pharmacol. 2004 Dec;54(6):497-504. Epub 2004 Jul 16.

PMID:
15258697
20.

Association of metabolic gene polymorphisms with tobacco consumption in healthy controls.

Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Boffetta P, Bouchardy C, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Coutelle C, Daly AK, Muzi G, Dolzan V, Duzhak TG, Farker K, Golka K, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Katoh T, Kihara M, Ono-Kihara M, Kim H, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, London S, Manni JJ, Maugard CM, Morgan GJ, Morita S, Nazar-Stewart V, Kristensen VN, Oda Y, Parl FF, Peters WH, Rannug A, Rebbeck T, Pinto LF, Risch A, Romkes M, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnett D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Zheng W, Pedotti P, Taioli E.

Int J Cancer. 2004 Jun 10;110(2):266-70.

21.

Signature of a silent killer: expression profiling in epithelial ovarian cancer.

Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM.

Expert Rev Mol Diagn. 2004 Mar;4(2):157-67. Review.

PMID:
14995903
22.

Metabolic gene polymorphism frequencies in control populations.

Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stücker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48.

23.

Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier.

Maugard CM, Charrier J, Pitard A, Campion L, Akande O, Pleasants L, Ali-Osman F.

Int J Cancer. 2001 Feb 1;91(3):334-9.

24.

Low frequency of microsatellite instability in BRCA1 mutated breast tumours.

Vaurs-Barrière C, Penault-Llorca F, Laplace-Marieze V, Presneau N, Maugard CM, Fiche M, Hardouin A, Bignon YJ.

J Med Genet. 2000 Oct;37(10):E32. No abstract available.

25.

Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes.

Fiche M, Avet-Loiseau H, Maugard CM, Sagan C, Heymann MF, Leblanc M, Classe JM, Fumoleau P, Dravet F, Mahé M, Dutrillaux B.

Int J Cancer. 2000 Sep 20;89(5):403-10.

26.

Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.

Fiche M, Avet-Loiseau H, Heymann MF, Moussaly F, Digabel C, Joubert M, Classe JM, Dravet F, Fumoleau P, Ross J, Maugard CM.

Int J Cancer. 1999 Oct 22;84(5):511-5.

27.

Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility.

Charrier J, Maugard CM, Le Mevel B, Bignon YJ.

Br J Cancer. 1999 Jan;79(2):346-53.

28.

Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility.

Maugard CM, Charrier J, Bignon YJ.

Chem Biol Interact. 1998 Apr 24;111-112:365-75.

PMID:
9679567

Supplemental Content

Loading ...
Support Center